How does sex hormone‑binding globulin (SHBG) change in reproductive‑age women with polycystic ovary syndrome, and what is the recommended evaluation and management?

Sex Hormone Binding Globulin in PCOS

In women with PCOS, sex hormone-binding globulin (SHBG) levels are characteristically decreased, and measuring SHBG (or calculating the free androgen index) should be part of the diagnostic evaluation to assess hyperandrogenemia. 1, 2

Understanding SHBG Changes in PCOS

The Pathophysiology

SHBG is a hepatically-produced glycoprotein that binds sex steroids with high affinity. In PCOS, a vicious cycle develops:

• Insulin resistance and hyperinsulinemia suppress hepatic SHBG production 3, 4
• Low SHBG levels increase the bioavailability of free (biologically active) androgens 4
• Elevated free androgens drive ovarian pathology, anovulation, hirsutism, and acne 5, 4

The evidence is clear: SHBG levels inversely correlate with PCOS severity. A 2018 meta-analysis demonstrated that SHBG levels in controls were significantly higher than in PCOS patients (SMD = -0.83,95% CI = -1.01, -0.64) 5. This relationship strengthens with increasing numbers of ovarian cysts 6.

Clinical Significance

Low SHBG is not merely a marker—it's mechanistically linked to metabolic dysfunction. SHBG levels negatively correlate with:

• Body mass index 6, 7
• Insulin resistance 7
• Non-alcoholic fatty liver disease 4
• Cardiovascular risk 8

Recommended Diagnostic Evaluation

Laboratory Assessment

Measure these parameters to diagnose hyperandrogenemia 1, 2:

1. Total testosterone (most important)
2. SHBG levels
3. Calculate Free Androgen Index (FAI): (Total testosterone ÷ SHBG) × 100 1

The FAI is particularly valuable because it accounts for the bioavailable androgen fraction. Free testosterone measurement is also acceptable but may be less standardized across laboratories 3, 9.

Additional Hormonal Testing

Complete the hyperandrogenism workup with 3, 9:

• Androstenedione (>10.0 nmol/L suggests adrenal/ovarian tumor)
• DHEAS to rule out non-classical congenital adrenal hyperplasia
• 17-hydroxyprogesterone if adrenal hyperplasia suspected

Metabolic Assessment

Because low SHBG correlates with insulin resistance, simultaneously evaluate 10, 2:

• Fasting glucose and 2-hour OGTT (75-gram glucose load) for diabetes screening
• Fasting insulin levels with glucose/insulin ratio
• Fasting lipid panel (total cholesterol, LDL, HDL, triglycerides)

The 2013 Endocrine Society guideline emphasizes that all women with PCOS require diabetes screening due to demonstrated increased risk 2.

Management Strategies to Improve SHBG

First-Line: Lifestyle Modification

Weight loss of just 5% improves metabolic and reproductive abnormalities in PCOS 10. The 2020 International Evidence-based Guideline establishes lifestyle management as first-line therapy 11:

• Multicomponent intervention: Combine calorie-restricted diet (500-700 kcal/day deficit), exercise (150 min/week moderate-high intensity aerobic activity), and behavioral strategies 1, 11
• Target: 5-10% weight loss 1
• Mechanism: Weight loss improves insulin sensitivity, which increases hepatic SHBG production and reduces free androgen levels 7

Recent 2025 meta-analysis data confirms that aerobic exercise specifically reduces total testosterone levels in PCOS women 12, likely through improved insulin sensitivity and increased SHBG.

Pharmacological Management

For Women NOT Attempting Conception

Combined oral contraceptive pills are first-line pharmacotherapy 10, 2:

• Mechanism: Suppress ovarian androgen secretion AND increase circulating SHBG levels 10
• Benefits: Regulate menstrual cycles, reduce hirsutism/acne, decrease endometrial cancer risk
• Caveat: May increase triglycerides and HDL cholesterol, though no evidence suggests increased cardiovascular events in PCOS versus general population 10

Insulin-sensitizing agents improve SHBG indirectly 10:

• Metformin: Improves insulin sensitivity, leading to increased SHBG production; beneficial for metabolic/glycemic abnormalities and menstrual irregularities 2, 5
• Thiazolidinediones: Have unfavorable risk-benefit ratio overall and are not recommended 2

The 2023 International Guideline update maintains these recommendations while emphasizing evidence-based medical therapy 13.

For Women Attempting Conception

Start with weight control and exercise, then add medication if needed 10:

1. Clomiphene citrate (first-line): 80% ovulation rate, 50% conception rate 10
2. Low-dose gonadotropins (if clomiphene fails): Reduces ovarian hyperstimulation risk 10
3. Metformin: Improves ovulation frequency but limited fertility benefit 2

Monitoring SHBG as a Therapeutic Target

SHBG may serve as both a diagnostic biomarker and therapeutic target 5, 4. Therapeutic interventions that improve SHBG levels reduce PCOS-associated complications 5. Consider serial SHBG measurements to:

• Track treatment response
• Assess metabolic improvement
• Guide therapy adjustments

Critical Pitfalls to Avoid

1. Don't rely on total testosterone alone—it misses cases where low SHBG elevates free androgens despite normal total levels 6
2. Don't use anti-Müllerian hormone (AMH) for diagnosis in adolescents—all guidelines recommend against this 1
3. Don't overlook vitamin D deficiency—present in 84% of PCOS patients and inversely correlated with SHBG and insulin resistance 7
4. Don't forget diabetes screening—use 2-hour OGTT, not just fasting glucose 10, 2
5. Recognize that older antiepileptic drugs (carbamazepine, phenobarbital, phenytoin) paradoxically increase SHBG production, potentially masking hyperandrogenism 3

Age-Specific Considerations

In adolescents: Diagnosis is problematic; hyperandrogenism must be central to presentation, and polycystic ovarian morphology should NOT be used as independent diagnostic criterion 1, 2

In aging women with PCOS: Despite greater declines in androgens and SHBG over time, they maintain higher androgen and lower SHBG levels than controls. An AMH cutoff of 1.17 ng/mL shows moderate diagnostic utility (AUC 0.71) 14